At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter Phase 2 Study of Nintedanib for Patients With Advanced Carcinoid Tumors
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Nintedanib, and 2 other interventions for Carcinoid Tumor and 2 related conditions. Completed, enrolled 32 participants across 2 sites.
Detailed Summary
This phase II trial studies how well nintedanib works in treating patients with neuroendocrine tumors that have spread from where they started to nearby tissue or lymph nodes (locally advanced) or have spread from the primary site (place where they started) to other places in the body (metastatic). Nintedanib may stop the growth of tumor cells by slowing or stopping a certain type of receptor called vascular endothelial growth factor receptor (VEGFR) from attaching to its target. This may stop the growth of neuroendocrine tumors by blocking the growth of new blood vessels necessary for tumor growth.
Study Details
Timeline
Interventions
Correlative studies
Given PO
Correlative studies
Ancillary studies